SEP 2 6 2006

10580615pro@sAdda (446)26

Approved for use through 04/30/03, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number. Substitute for form 1449/PTO

> INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known Application Number 10/580,615 Filing Date May 23, 2006 First Named Inventor John William Benbow Art Unit TBA Examiner Name TBA Attorney Docket Number PC26084A

THADBARAT!	<b>7</b> /		U.S. PATE	ENT DOCUMENTS	
EXAMINER INITIAL	Cite No. 1	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	6,387,931			Withdrawn
	АВ	3,819,706	06-25-1974	Mehta, N.	
	AC	3,885,046	05-20-1975	Mehta, N.	
	AD	4,007,196	02-08-1977	Christensen, J., et al	
	AE	4,085,225	04-18-1978	Welle. J., et al	
	AF	4,314,081	02-02-1982	Molloy, B., et al.	
	AG	4,338,317	07-06-1982	Temple, Jr., D., et al	
	АН	4,423,049	12-27-1983	Temple, Jr., D.	
	Al	4,535,186	08-13-1985	Husbands, G., et al	
	AJ	4,536,518	08-20-1985	Welch, Jr., W., et al	
	AK	4,690,931	09-01-1987	Wick, A., et al	
***	AL	4,804,663	02-14-1989	Kennis, L., et al	
	AM	4,833,142	05-23-1989	Hartog, J., et al	
	AN	4,895,841	01-23-1990	Sugimoto, H., et al	
	AO	4,948,807	08-14-1990	Rosin, M., et al	
	AP.	5,122,525	06-16-1992	Bright, G., et al	
	AQ	5,162,339	11-10-1992	Lowe III, J.	,

EXAMINER:	/Samantha Shterengarts/	DATE CONSIDERED:	08/25/2008

EVALUATE: Initial if reference considered, whether or and casine is in conformance and harder 2000. Does line through criticals in conformance and an exactive in the conformance in the conformance and an exactive in the conformance in

This collection of information is required by 37 CFR. 14.97 and 1.98. The information is required to obtain or retains a benefit by the public, which is to file (and by the USPTO to process) as application. Confidentiality is governed by 37 U.S.C. 122 and 37 UFR. 14. This collection estimated is subtained by the public, which is to file (and by the USPTO to process) as application. Confidentiality is governed by 37 U.S.C. 122 and 37 UFR. 14. This collection estimated is subtained as the public, which is to file (and by the USPTO to process) as application. Confidentiality is governed by 37 U.S.C. 122 and 37 UFR. 14. This collection estimated by the use of the USPTO to process) as application. Confidentiality as governed by 37 U.S.C. 122 and 37 UFR. 14. This collection of information of the USPTO to process) as application. Confidentiality as a possible of the USPTO to process as application. Confidentiality as a possible of the USPTO to process as application. Confidentiality as a possible of the USPTO to process as a possible of the USPTO to

10580615pt@sAdda (d4626

Approved for use through 04/30/03. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. Department of Commerce Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known			
Application Number	10/580,615		
Filing Date	May 23, 2006		
First Named Inventor	John William Benbow		
Art Unit	TBA		
Examiner Name	TBA		
Attorney Docket Number	PC26084A		

 AR	5,185,343	02-09-1993	Chenard, B.
AS	5,229,382	07-20-1993	Chakrabarti, J., et al
ΑŢ	5,232,929	08-03-1993	Desai, M., et al
AU	5,240,958	08-31-1993	Campion, C., et al
AV	5,272,160	12-21-1993	Chenard, B.
AW	5,310,763	05-10-1994	Campion, C., et al
AX	5,312,925	05-17-1994	Allen, D., et al
AY	5,332,817	07-26-1994	Desai, M., et al
AZ	5,356,905	10-18-1994	Butler, T.
ВА	5,358,948	10-25-1994	Bradshaw, K.
ВВ	5,373,018	12-13-1994	Cugola, A., et al
ВС	5,455,258	10-03-1995	MacPherson, L., et al
BD	5,466,823	11-14-1995	Talley, J., et al
BE	5,474,995	12-12-1995	Ducharme, Y., et al
BF	5,506,242	04-09-1996	MacPherson, L., et al
 BG	5,510,350	04-23-1996	Oxford, A., et al
вн	5,530,161	06-25-1996	Campion, C., et al
ВІ	5,538,984	07-23-1996	Villalobos, A., et al
ВЈ	5,552,419	09-03-1996	MacPherson, L., et al
ВК	5,587,458	12-24-1996	King, C., et al

EXAMINER:

/Samantha Shterengarts/

DATE CONSIDERED:

08/25/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to projection. Applicant's unique chimon estimated experiences, the instance of the control of the

This collection of information is required by 37 CFR. 1.97 and 1.98. The information is required to obtain or retain n benefit by the public, which is to Sile (and by the USPTO to process) as application. Confidentially is governed by 37 US C. 122 and 37 UTR. 1.47. This collection is estimated to sake 2 howers to complex, including gathering, preparing, and admining plot completed any confidential to the confidential to th

10580615ptc@Adda (d4626

Approved for use through 04/30/03, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. Department of Commerce

10/580,615

PC26084A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number. Complete if Known

Application Number

Attorney Docket Number

Substitute for form 1449/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Filing Date May 23, 2006 John William Benbow First Named Inventor TBA Art Unit TBA Examiner Name

BL	5,602,169	02-11-1997	Hewawasam, P., et al
вм	5,633,272	05-27-1997	Talley, J., et al
BN	5,672,615	09-30-1997	MacPherson, L., et al
во	5,679,683	10-21-1997	Bridges, A., et a;
ВР	5,703,240	12-30-1997	Armour, D., et al
BQ	5,716,965	02-10-1998	Ito, F., et al
BR	5,719,147	02-17-1998	Dorn, C., et al
BS	5,744,480	04-28-1998	Lowel II, J., et al
вт	5,744,483	04-28-1998	Butler, T., et al
BU	5,747,498	05-05-1998	Schnur, R., et al
BV	5,763,699	06-09-1998	German, L., et al
BW	5,773,450	06-30-1998	Lowe III, J., et al
вх	5,792,783	08-11-1998	Tang, P., et al
BY	5,807,867	09-15-1998	Ito, F., et al
BZ	5,834,504	11-10-1998	Tang, P., et al
CA	5,843,966	12-01-1998	Armour, D., et al
СВ	5,851,999	12-22-1998	Ullrich, A., et al
СС	5,852,038	12-22-1998	Ito, F., et al
CD	5,861,510	01-19-1999	Piscopio, A., et al
CE	5,863,949	01-26-1999	Robinson, R., et al

EXAMINER:

/Samantha Shterengarts/

DATE CONSIDERED:

08/25/2008

EXAMENT: this if effective considered, where or are claims in its conformance with MEPT PIO. Does for through chiefes of each conformance and not considered to the conformance and not conformance

This collection of discharation is required by 1 SCR 1.87 and 1.95. The information is required to settle or service a board by the pack, which is no file of the yells in IEEE/TO to preceip in any policies. Conferentially in generally \$1/5/0.5.1/2.22 and 17 CR 1.14. This collection is entirement and that 2 houses to employe including pulsation, preprints, set also indicates give a complete operation from the 15/17/0.1 for this view preprints are present to the preprint of t

10580615PTGAMBK(44626

Approved for use through 04/30/03. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Substitute for form 1449/PTO

Complete if Known		
Application Number	10/580,615	
Filing Date	May 23, 2006	
First Named Inventor	John William Benbow	
Art Unit	TBA	
Examiner Name	TBA	
Attorney Docket Number	PC26084A	

	CF	5,877,305	03-02-1999	Huston, J., et al
	CG	5,883,113	03-16-1999	Tang, P., et al
	СН	5,886,020	03-23-1999	Tang, P., et al
	CI	5,886,009	03-23-1999	Ito, F., et al
	CJ	5,932,595	08-03-1999	Bender, S., et al
	ск	5,939,433	08-17-1999	Ito, F., et al
	CL	5,962,472	10-05-1999	Bourson, A., et al
	СМ	5,994,351	11-30-1999	Robinson, R., et al
	CN	6,046,213	04-04-2000	Chenard, B., et al
	со	6,051,593	04-18-2000	Tang, P., et al
	СР	6,077,864	06-20-2000	Burgess, L., et al
	cq	6,087,392	07-11-2000	Reiter, L.
	CR	6,090,852	07-18-2000	Dack, K., et al
	cs	6,110,964	08-29-2000	Robinson, R.
	СТ	6,114,371	09-05-2000	Tang, P., et al
	CU	6,124,317	09-26-2000	Bigge, C., et al
	cv	6,124,323	09-26-2000	Bigge, C., et al
	cw	6,130,234	10-10-2000	Bigge, C., et al
	СХ	6,133,305	10-17-2000	Tang, P., et al
	CY	6,147,061	11-14-2000	Reiter, L.
EVANAIN		1 01		DATE CONSIDERED:

FXAMINER: DATE CONSIDERED: /Samantha Shterengarts/ 08/25/2008

EXAMINEE. Initial inference considered, whether or not classics is in conformance with ARPE 900. There is through classed in they is conformance and not exceeded. Incidence type of this time with tere communication or conformation of the conforma

This collection of information is required by 31 CER, 14.7 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (sell by the USPTO to process) an application. Confidentiality a governed by 31 SER, 122 and 31 CER, 14.8 This collection is estimated to take 2 hours to complex, including pubring, preparing, and absorbing the complete despitation from the USPTO. Three will way depending upon the included and a reasonal of time by our report to treat the confidence of the Complete of the Complete

10580615PTG(6)Ad8A:(0)4036 Approved for use through 04/30/03. OMB 0651-0031 Receipt date: 09/26/2006

U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number. Substitute for form 1449/PTO

> INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known		
Application Number	10/580,615	
Filing Date	May 23, 2006	
First Named Inventor	John William Benbow	
Art Unit	TBA	
Examiner Name	TBA	
Attorney Docket Number	PC26084A	

-

DATE CONSIDERED: FXAMINER: 08/25/2008 /Samantha Shterengarts/

EXAMINER. Initial inference considered, whole or or at ration is in conformance with MEPT POP. One The flow droph princip if not in conformance and an excession in Induce copy of this flow with next communications on the conformance of the c

This collection of information is required by 37 LCR, 147 and 1.91. The information is required to obtain or resin a bornelit by the public, which is to the first by the USFTOD precept in application. Confidentiality is governed by 37 LCR, 122 and 17 CFR, 146. This collection is estimated to take 2 born to complete, including pathering, preparing, and submitting the complete of application from the USFTOD The received by the Confidence of the Confidentiality is governed to pictural the control of the Confidentiality is governed to pictural the control of the Confidentiality is governed to pictural the control of the Confidentiality is governed to pictural the control of the Confidentiality is governed to pictural the confidentiality of the Confidentiality is governed to Confidentiality in the Confidentiality of the

Receipt date: 09/26/2006 10580615-FCGB/deb:(04626 Approved for use through 04/30/03. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Substitute for form 1449/PTO

Complete if Known			
	Application Number	10/580,615	
	Filing Date	May 23, 2006	
	First Named Inventor	John William Benbow	Т
	Art Unit	TBA	
	Examiner Name	TBA	
	Attorney Docket Number	PC26084A	

	DU	6,462,048 1	0-08-2002	Howard, H.		_	
		F	OREIGN PAT	TENT DOCUMENTS		_	
EXAMINER INITIAL	Cite No. 1	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kin Code <sup>5</sup> (if known)	Publication d Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	
	DV	WO 02/18346	03-07-2002	Pfizer Products Inc		L	
	DW	WO 98/34915	08-13-1998	Pfizer Inc	*	L	
	DX	WO 98/34918	08-13-1998	Pfizer Inc		L	
	DY	WO 98/14451	04-09-1998	Novartis AG		L	
	DZ	WO 99/24440	05-20-1999	Pfizer Products Inc		$\vdash$	
	EA	WO 97/13760	04-17-1997	Glaxo Group Limited		L	
	EB	WO 99/35132	07-15-1999	Glaxo Group Limited		L	
	EC	WO 99/35146	07-15-1999	Glaxo Group Limited		L	
	ED	WO 94/21619	09-29-1994	Pfizer Inc			
	EE	WO 97/23202	07-03-1997	State of Oregon			
	EF	WO 98/18793	05-07-1998	Merck Patent GMBH	No English Equiv.	L	
				ERATURE DOCUMENT	·		
Examiner Initials	Cite No.1	Include name of the author magazine, journal, serial, sy where published.	(in CAPITAL LETTE imposium, catalog, o	RS), title of the article (when appropetc.), date, page(s), volume-issue nu	riate), title of the item (book, mber(s), publisher, city and/or country	T²	
	EG	ALI, A., et al., "Glycogen Synthase Kinase-3: Properties, Functions, And Regulation," Chem. Rev., 2001, 2527-2540, vol. 101.					
	EH	BAAR, K., et al., "Phos Following Resistance	sphorylation Of Exercise," Am.	p70 <sup>S6k</sup> Correlates With Increa <i>I. Physiol.</i> , 1999, C120-C127	sed Skeletal Muscle Mass , vol. 276.		
EXAMINE	₹:	/Samantha Shte	erengarts/	DATE CONSIDERED	08/25/2008		

applicant: Applicant's unique citation designation number (opinous). "See Kinds Codes of USPTO Patent Documents as \*\*new.uppto gover AMPEP 901 A.\* Earner Office that issued the document, by the two-letter code (WIPC)
Standard S.13." For Injustracy power documents, the indication of the year of the right of the Emperor must proced the tenth number of the patent document. "Kinded document by the appropriate yambob as indicated on the
document under WIPC Substantial's Toll Front Substantial's T This collection of information is required by 37 CFR. 147 and 1.98. The information is required to dotte or remain a benefit by the public, which is to file (and by the USFTO a precent in a spiciotien. Confederation) in government by 37 USFR. 142 and 37 CFR. 147 and 1.98. The information is required to dotte or remain a benefit by the public, which is to file (and by the USFTO a precent in any incidence of the USFTO and the USFTO an

105806159TC36A6A;04626 Approved for use through 04/30/03. OMB 0651-0031 Receipt date: 09/26/2006

U.S. Patent and Trademark Office; U.S. Department of Commerce

PC26084A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number Substitute for form 1449/PTO Complete if Known

	Complete II Known		
	Application Number	10/580,615	
INCORMATION DISCUSSIBLE	Filing Date	May 23, 2006	
	First Named Inventor	John William Benbow	
	Art Unit	TBA	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Examiner Name	TBA	

Attorney Docket Number

El	BADORFF, C., et al., "Fas Receptor Signaling Inhibits Glycogen Synthase Kinase 39 And Induces Cardiac Hypertrophy Following Pressure Overload," <i>The Journal Of Clinical Investigation</i> , 2002, 373-381, vol. 109, no. 3.
 EJ	BARNES, P., "Cytokine Modulators As Novel Therapies For Asthma," Ann. Rev. Pharmacol. Toxicol., 2002, 81-98, vol. 42.
EK	BEALS, C., et al., "Nuclear Export Of NF-ATc Enhanced By Glycogen Synthase Kinase-3," Science, 1997, 1930-1933, vol. 275.
EL	BERGE, S., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977, 1-19, vol. 66, no. 1.
ЕМ	BRUNN, G., et al., "Phosphorylation Of The Translational Repressor PHAS-I By The Mamalian Target Of Rapamycin," Science, 1997, 99-101, vol. 277.
EN	CASTRO A., et al., "Inhibition Of Tau Phosphonylation: A New Therapeutic Strategy For The Treatment Of Alzheimer's Disease And Other Neurodegenerative Disorders," <i>Expert Opinion On Therapeutic Patents</i> , 2000, 1519-1527, vol. 10, no. 10.
EO	COHEN, P., "The Role Of Protein Phosphorylation In Human Health And Disease Delivered On June 30th 2001 At the FEBS Meeting In Lisbon," <i>Eur. J. Blochem.</i> , 2001, 5001-5010, vol. 268.
EP	CROSS, D., et al., "Selective Small-Molecule Inhibitors Of Glycogen Synthase Kinase-3 Activity Protect Primary Neurones From Death," <i>Journal Of Neurochemistry</i> , 2001, 94-102, vol. 77.
EQ	EASTMAN, Q., et al., "Regulation Of LEF-1/TCF Transcription Factors By Wnt And Other Signals," Current Opinion in Cell Biology, 1999, 233-240, vol. 11.
ER	ELDAR-FINKELMAN, H., "Glycogen Synthase Kinase 3: an Emerging Therapeutic Target," Trends In Molecular Medicine, 2002, 126-132, vol. 8, no. 3.
ES	EMBI, N., et al., "Glycogen Synthase Kinase-3 From Rabbit Skeletal Muscle," Euro. J. Bicochem, 1980, 519-527, vol. 107.
ET	FUCHS, E., et al., "At The Roots Of A Never-Ending Cycle," Developmental Cell, 2001, 13-25, vol. 1.
EU	GRIMES, C., et al., "The Multifaceted Roles Of Glycogen Synthase Kinase 3β In Cellular Signaling," <i>Progress In Neurobiology</i> , 2001, 391-426, vol. 65.
EV	HAQ, S., et al., "Glycogen Synthase Kinase-3ß Is A Negative Reulator Of Cardiomyocyte Hypertrophy, "The Journal Of Cell Biology, 2000, 117-129, vol. 151, no. 1.

EXAMINER:	/Samantha Shterengarts/	DATE CONSIDERED:	08/25/2008

EXAMINE: initial if reference considered, whether or oricinization is a conformance with MEPF 409. Does line through cinition if an is conformance and not considered. Include copy of this form with next communication and explainal. Mysican is required unique casined resignation and project and for section manner (positional.) See facing Color and Control (1970). The memory of the form is conformance and one control in the control in the

This officience of information is required by 37 CFIL 197 at 18. The information is required to design or main a benefit by the public, which is to fife (and by the TSTO) to precent paragraphics and proceeding the public of the proceeding and the public of the public

105806159T0GFANA;(0\$626 Approved for use through 04/30/03. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number. Complete if Known Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known		
Application Number	10/580,615	
Filing Date	May 23, 2006	
First Named Inventor	John William Benbow	
Art Unit	TBA	
Examiner Name	TBA	
Attorney Docket Number	PC26084A	

EW	KIM, L., et al., "GSK3, A Master Switch Regulating Cell-Fate Specification And Tumorigenesis," Current Opinion In Genetics & Development, 2000, 508-514, vol. 10.
EX	KLEIN, P., et al., "A Molecular Mechanism For The Effect Of Lithium On Development," Proc. Natl. Acad. Sci. USA, 1996, 8455-8459, vol. 93.
EY	LAU, K., et al., "Expression Analysis Of Glycogen Synthase Kinase-3 In Human Tissues," J. Peptide Res., 1999, 85-91, vol. 54.
EZ	MEIJER, L., et al., "Properties And Potential Applications Of Chemical Inhibitors Of Cyclin- Dependent Kinases," <i>Pharmacol. And Ther.</i> , 1999, 279-284, vol. 82, nos. 2-3.
FA	MILLAR, S., et al., "WNT Signaling In The Control Of Hair Growth And Structure," Developmental Biology, 1999, 133-149, vol. 207.
FB	NIKOULINA, S., et al., "Inhibition Of Glycogen Synthase Kinase 3 Improves Insulin Action And Glucose Metabolism In Human Skeletal Muscle," <i>Diabetes</i> , 2002, 2190-2198, vol. 51.
FC	ORENA, S., et al., "Inhibition Of Glycogen-Synthase Kinase 3 Stimulates Glycogen Synthase And Glucose Transport By Distinct Mechanisms In 3T3-L1 Adipocytes," The Journal of Biological Chemistry, 2000, 15765-15772, vol. 275, no. 21.
FD	REGAN, J., et al., "Pyrazole Urea-Based Inhibitors Of p38 MAP Kinase: From Lead Compound To Clinical Candidate," <i>J. Med. Chem.</i> , 2002, 2994-3008, vol. 45.
FE	RHOADS, R., et al., "Signal Transduction Pathways That Regulate Eukaryotic Protein Synthesis," The Journal Of Biological Chemistry, 1999, 30337-30340, vol. 274, no. 43.
FF	SASAKI, C., et al., "Different Expression Of Glycogen Synthase Kinase-3ß Between Young And Old Rat Brains After Transient Middle Cerebral Artery Occlusion," <i>Neurological Research</i> , 2001, 588-592, vol. 23.
FG	SAUSVILLE, E., et al., "Cyclin-Dependent Kinases: Initial Approaches To Explioit a Novel Therapeutic Target," Pharmacol. And Ther., 1999, 285-292, vol. 82, nos. 2-3.
FH	SUMMERS, S., et al., "The Role of Glyocgen Synthase Kinase 3β In Insulin-Stimulated Glucose Metabolism," The Journal of Biological Chemistry, 1999, 17934-17940, vol. 274, no. 25.
FI	TONG, H., "Phosphorylation Of Glycogen Synthase Kinase-3β During Preconditioning Through A Phosphatidylinositol-3-Kinase-Dependent Pathway Is Cardioprotective," et al., Circulation Research, 2002, 377-379, vol. 90.
FJ	VIJAYARAGHAVAN, S., et al., "Sperm Motility Development In The Epididymis Is Associated With Decreased Glycogen Synthase Kinase-3 And Protein Phosphatase 1 Activity," <i>Biology Of Reproduction</i> , 1996, 709-718, vol. 54.

EXAMINER:	/Samantha Shterengarts/	DATE CONSIDERED:	08/25/2008	
	g .			

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MEFF 09. Darse into though citation if not in conformance and not exempted. Headed copy of this firm with not incommon citation. The conformal interest is the conformal interest in the conformal interest interest countered, the conformal interest interest countered in the conformal interest interest in the conformal interest interest interest in the conformal interest inter

This collection of information is required by 17 (CR). 17 (CR) at 18.1 The information is required to design or region is breatly for the public, which is not first only by at 18 (ER) to present its application. Conferentiality is generally by 13 (LS). 12 at 19 (TM). 10 This collection is coincided and that 20 have been required, including public integers in the complete design into the most in the ISPTO. IT must be to 18 (ER) to present a position in the ISPTO. IT must be in US reporting a present in the ISPTO. IT must be in US reporting in US rep

10580615ptc@Adak:d46a26

Approved for use through 04/30/03, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. Department of Commerce Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number. Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known			
Application Number	10/580,615		
Filing Date	May 23, 2006		
First Named Inventor	John William Benbow		
Art Unit	TBA .		
Examiner Name	TBA		
Attorney Docket Number	PC26084A		

-	FK	VYAS, D., et al., "GSK-3β Negatively Regulates Skeletal Myotube Hypertrophy," Am. J. Physiol. Cell Physiol., 2002, C545-C551, vol. 283	
	FL	WILLIAMS, R., et al., "Lithium Therapy And Signal Transduction," TIPS, 2000, 61-64, vol. 21.	
	FM	WOODGETT, J., "Molecular Cloning And Expression Of Glycogen Synthase Kinase-3/Factor A," The EMBO Journal, 1990, 2431-2438, vol. 9, no. 8.	

EXAMINER:	/Samantha Shterengarts/	DATE CONSIDERED:	08/25/2008

EXAMENER, Initial Federace considered, whether or not citation is a conformance with MPEP 600. Done to through citation if the in conformance and not considered, funded copy of this form with next communication of the properties. Application is required under the conformation of the properties of the Emperor many properties the similar handles of the properties of the P

This collection of information is required by 37 CFR. 197 and 198. The information is required to obtain or retain a benefit by the public, which is to file (end by the USPTO to process) as application. Confidentiality is premented by 37 USF. 121 and 37 USFR. 114. This collection is estimated to take 2 labora to complete, including publicing, preparing, and submitting the complete deployation forms to the USPTO. The will vary depending publicing. Preparing and submitting the complete deployation forms to the USPTO. The will vary depending the complete deployation forms to the USPTO. The will vary depending the complete deployation forms to the USPTO. The will vary depending the complete deployation forms to the USPTO. The value vary deployation forms to the USPTO. Th